Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2015 1
2018 1
2019 3
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Ribociclib-induced Vitiligo: a Case Report.
Silvestre Torner N, Aguilar Martínez A, Echarri González MJ, Tabbara Carrascosa S, Román Sainz J, Gruber Velasco F. Silvestre Torner N, et al. Among authors: echarri gonzalez mj. Dermatol Pract Concept. 2022 Apr 1;12(2):e2022045. doi: 10.5826/dpc.1202a45. eCollection 2022 May. Dermatol Pract Concept. 2022. PMID: 35646430 Free PMC article. No abstract available.
Effects of Physical Activity Interventions on Self-Perceived Health Status among Lung Cancer Patients: Systematic Review and Meta-Analysis.
Barrera-Garcimartín A, Sánchez-Polán M, López-Martín A, Echarri-González MJ, Marquina M, Barakat R, Cordente-Martínez C, Refoyo I. Barrera-Garcimartín A, et al. Among authors: echarri gonzalez mj. Cancers (Basel). 2023 Nov 28;15(23):5610. doi: 10.3390/cancers15235610. Cancers (Basel). 2023. PMID: 38067317 Free PMC article. Review.
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.
Pérez Ramírez S, Del Monte-Millán M, López-Tarruella S, Martínez Jáñez N, Márquez-Rodas I, Lobo Samper F, Izarzugaza Perón Y, Rubio Terres C, Rubio Rodríguez D, García-Sáenz JÁ, Moreno Antón F, Zamora Auñón P, Arroyo Yustos M, Lara Álvarez MÁ, Ciruelos Gil EM, Manso Sánchez L, Echarri González MJ, Guerra Martínez JA, Jara Sánchez C, Bueno Muiño C, García Adrián S, Carrión Galindo JR, Valentín Maganto V, Martín M. Pérez Ramírez S, et al. Among authors: echarri gonzalez mj. Clin Transl Oncol. 2020 May;22(5):717-724. doi: 10.1007/s12094-019-02176-x. Epub 2019 Jul 12. Clin Transl Oncol. 2020. PMID: 31300934
Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Rosell R, et al. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692684 Free article.
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L, Moreno Antón F, Izarzugaza Perón Y, Delgado Mingorance JI, Borrega García P, Echarri González MJ, Martínez-Jañez N, López-González A, Olier Garate C, Ballesteros García A, Chacón López-Muñíz I, Ciruelos Gil E, García-Sáenz JA, Paz-Ares L. Manso L, et al. Among authors: echarri gonzalez mj. Breast J. 2019 Mar;25(2):219-225. doi: 10.1111/tbj.13199. Epub 2019 Feb 8. Breast J. 2019. PMID: 30734437 Clinical Trial.